The first faecal transplant therapy derived from the gut microbiome of healthy donors was approved by the US Food and Drug Administration on 30 November, paving the way for regulatory reviews of other products in the sector. The therapy, Rebyota, was developed by Ferring Pharmaceuticals Inc and approved for the prevention of recurrent Clostridioides difficile infection, a potentially life-threatening disease.
Cancer Research Horizons, a division of the UK charity Cancer Research UK, is to work with the Karolinska Institutet over the next five years to identify new opportunities for cancer treatments and move these projects forward through industrial partnerships.
AstraZeneca Plc is to acquire a Dutch company with technology for developing T cell therapies for cancer which target antigens specific to a patient’s tumour. The company, Neogene Therapeutics Inc, was founded in Amsterdam, the Netherlands in 2018 and has a pipeline of candidate therapies that consist of engineered T cells equipped with receptors targeting tumour-specific antigens, also known as neoantigens.
Public Health
Climate change is transforming
infectious disease
By Liam Tremble
Regulation and Policy
Regulatory framework for
real-world data progresses
By Chantal van Gils
The Inventive Step
Interview with
NEUWAY Pharma GmbH
Global Health
WHO identifies fungal
pathogens of concern
By Peter Charlish
Oncology Review
Progressive increase in
oncology drug approvals
By Vittore Tamassia and
Bruno Pagliara
